Genmab A-S

Genmab A-S

Yahoo Finance • 7 days ago

Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?

Genmab has seen a sharp rerating on the back of recent oncology trial successes, which puts a fresh spotlight on whether the current share price lines up with the cash flows its pipeline may ultimately produce. With the stock now reflectin... Full story

Yahoo Finance • 8 days ago

Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50%

Genmab scores a ‘hat trick’ with positive data for its experimental cancer drug, petosemtamab, Jefferies says. Continue Reading... Full story

Yahoo Finance • 10 days ago

Genmab shares jump 13% on colorectal cancer drug trial results

Investing.com -- Genmab shares jumped as much as 13% on Monday after the Danish biotech said its experimental drug petosemtamab, combined with chemotherapy, shrank tumours in 75% of previously untreated patients with advanced colorectal ca... Full story

Yahoo Finance • 11 days ago

Genmab, Incyte team up to develop experimental colorectal cancer treatment

[Incyte headquarters in Wilmington, Delaware, USA] JHVEPhoto/iStock Editorial via Getty Images Genmab (GMAB [https://seekingalpha.com/symbol/GMAB]) and Incyte (INCY [https://seekingalpha.com/symbol/INCY]) announced a clinical trial collab... Full story

Yahoo Finance • 12 days ago

Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)?

Incyte and Genmab A/S announced a clinical trial collaboration to test INCB161734 with petosemtamab and standard chemotherapy in first line KRAS G12D mutated metastatic colorectal cancer, with Genmab running the Phase 1/2 study and Incyte... Full story

Yahoo Finance • 12 days ago

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--(BUSINESS WIRE)--Ge... Full story

Yahoo Finance • 12 days ago

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) WILMINGTON, Del. & COPENHAGEN, Denmark, October 24, 2026--(BUSINESS WIRE)--In... Full story

Yahoo Finance • 13 days ago

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator's choice chemotherapy Results demons... Full story

Yahoo Finance • 21 days ago

What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?

AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 results for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The EPCORE DLBCL-2 study showed a statistically significant reduction in the risk of disease progr... Full story

Yahoo Finance • 22 days ago

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Equity InsiderNews Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United Sta... Full story

Yahoo Finance • 23 days ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026

Genmab A/S Company Announcement Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN,... Full story

Yahoo Finance • 29 days ago

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members

Genmab A/S Company Announcement COPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting. At the Extraordinary General Meeting the proposal from the Board of Directors on... Full story

Yahoo Finance • 29 days ago

Genmab (CPSE:GMAB) Posts Two Strong Trial Readouts, Is The Valuation Now Too Hard To Ignore?

Genmab stock: what the latest trial results mean for investors Genmab (CPSE:GMAB) is suddenly back on many watchlists after two fresh clinical readouts in oncology, including a Phase 3 win for epcoritamab in newly diagnosed diffuse large... Full story

Yahoo Finance • 29 days ago

AbbVie (ABBV) Cut Frontline DLBCL Progression Or Death Risk By 51%

AbbVie (NYSE:ABBV) and Genmab reported positive topline Phase 3 EPCORE DLBCL-2 data for epcoritamab plus R-CHOP in newly diagnosed DLBCL. The combination reduced the risk of disease progression or death by 51% versus standard R-CHOP alone,... Full story

Yahoo Finance • 30 days ago

Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?

Genmab A/S Sponsored ADR (GMAB) shares rallied 10.7% in the last trading session to close at $38.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to th... Full story

Yahoo Finance • last month

AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer Contender

The addition of Genmab's Epkinly to a standard cocktail of drugs helped lymphoma patients live longer before worsening. Genmab stock rocketed. Continue Reading... Full story

Yahoo Finance • last month

Genmab stock surges 11% on positive cancer drug trial data

Investing.com -- Genmab A/S (NASDAQ:GMAB) shares rose 11% Monday afternoon following the announcement of positive topline results from a Phase 3 trial of epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymph... Full story

Yahoo Finance • last month

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B... Full story

Yahoo Finance • last month

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Genmab A/S Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically... Full story

Yahoo Finance • 2 months ago

Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?

Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion. The upward revision underscores the strong commercial mo... Full story